CSL News: CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durab - 24th Feb 2023, 12:00am

[annb0t]

Data follow the historic approval of the first gene therapy for hemophilia B, which reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy and generates elevated and sustained factor IX levels for years after a one-time infusion 18-month data support the efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment HEMGENIX® is approved for adults with hemophilia B in the United States, European Union and European Economic Area

KING OF PR...

>>> Read more: CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)